Literature DB >> 11591513

Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.

J L Neumeyer1, X H Gu, L A van Vliet, N J DeNunzio, D E Rusovici, D J Cohen, S S Negus, N K Mello, J M Bidlack.   

Abstract

A series of new N-substituted derivatives of morphinan was synthesized and their binding affinity for the three opioid receptors (mu, delta, and kappa) was determined. A paradoxical effect of N-propargyl (MCL-117) and N-(3-iodoprop-(2E)-enyl) (MCL-118) substituents on the binding affinities for the mu and kappa opioid receptors was observed. All of these novel derivatives showed a preference for the mu and kappa versus delta binding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591513     DOI: 10.1016/s0960-894x(01)00543-1

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

Review 1.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

2.  High-affinity carbamate analogues of morphinan at opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem Lett       Date:  2007-01-17       Impact factor: 2.823

3.  Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.

Authors:  Michael Decker; Brian S Fulton; Bin Zhang; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

4.  Aminothiazolomorphinans with mixed κ and μ opioid activity.

Authors:  Tangzhi Zhang; Zhaohua Yan; Anna Sromek; Brian I Knapp; Thomas Scrimale; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2011-02-25       Impact factor: 7.446

Review 5.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

6.  In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem       Date:  2007-03-30       Impact factor: 3.641

7.  Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice.

Authors:  Jian-feng SUN; Yu-hua WANG; Fu-ying LI; Gang LU; Yi-min TAO; Yun CHENG; Jie CHEN; Xue-jun XU; Zhi-qiang CHI; John L NEUMEYER; Ao ZHANG; Jing-gen LIU
Journal:  Acta Pharmacol Sin       Date:  2010-11-22       Impact factor: 6.150

Review 8.  Molecular targets of opiate drug abuse in neuroAIDS.

Authors:  K F Hauser; N El-Hage; S Buch; J R Berger; W R Tyor; A Nath; A J Bruce-Keller; P E Knapp
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

Review 9.  Agents in development for the management of cocaine abuse.

Authors:  David A Gorelick; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.

Authors:  Yu-Jun Wang; Yi-Min Tao; Fu-Ying Li; Yu-Hua Wang; Xue-Jun Xu; Jie Chen; Ying-Lin Cao; Zhi-Qiang Chi; John L Neumeyer; Ao Zhang; Jing-Gen Liu
Journal:  J Pharmacol Exp Ther       Date:  2009-01-09       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.